Literature DB >> 24825017

Palliative sedation for intolerable suffering.

Marco Maltoni1, Emanuela Scarpi, Oriana Nanni.   

Abstract

PURPOSE OF REVIEW: The purpose of this review is to provide an update on palliative sedation in palliative and end-of-life care. Palliative sedation is the medical procedure used to deal with refractory symptoms in advanced cancer patients when all other specific approaches have failed. RECENT
FINDINGS: Palliative sedation, in the strictest sense of the term, is a proportionate (proportionate palliative sedation, PPS) and intrinsically variable procedure used on an individual basis to relieve refractory symptoms in terminally ill patients, without the intention of hastening death. Completely separate from any other end-of-life decision and not intended to hasten death, palliative sedation has been shown not to have a detrimental impact on survival.
SUMMARY: To maintain palliative sedation as a legitimate clinical procedure from any ethical or clinical point of view, it must be limited to the restricted area for which it was conceived, that is, relief from refractory suffering as deemed necessary by a patient and by an experienced palliative care team. In this way, there is no risk of associating palliative sedation with other end-of-life decisions. Close collaboration is needed between oncologists and palliative care physicians for this clinical procedure.

Entities:  

Mesh:

Year:  2014        PMID: 24825017     DOI: 10.1097/CCO.0000000000000097

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  5 in total

1.  Supportive/palliative care in cancer patients: quo vadis?

Authors:  Jean Klastersky; Isabelle Libert; Bénédicte Michel; Myriam Obiols; Dominique Lossignol
Journal:  Support Care Cancer       Date:  2015-10-14       Impact factor: 3.603

2.  Do palliative care patients and relatives think it would be acceptable to use Bispectral index (BIS) technology to monitor palliative care patients' levels of consciousness? A qualitative exploration with interviews and focus groups for the I-CAN-CARE research programme.

Authors:  Anna-Maria Krooupa; Patrick Stone; Stephen McKeever; Kathy Seddon; Sarah Davis; Elizabeth L Sampson; Adrian Tookman; Jonathan Martin; Vinnie Nambisan; Bella Vivat
Journal:  BMC Palliat Care       Date:  2022-05-24       Impact factor: 3.113

Review 3.  Palliative Sedation for the Terminally Ill Patient.

Authors:  Ferdinando Garetto; Ferdinando Cancelli; Romina Rossi; Marco Maltoni
Journal:  CNS Drugs       Date:  2018-10       Impact factor: 5.749

4.  Midazolam sedation in palliative medicine: retrospective study in a French center for cancer control.

Authors:  Vincent Gamblin; Vincent Berry; Emmanuelle Tresch-Bruneel; Michel Reich; Arlette Da Silva; Stéphanie Villet; Nicolas Penel; Chloé Prod'Homme
Journal:  BMC Palliat Care       Date:  2020-06-19       Impact factor: 3.234

5.  Palliative care specialists in hospice and hospital/community teams predominantly use low doses of sedative medication at the end of life for patient comfort rather than sedation: Findings from focus groups and patient records for I-CAN-CARE.

Authors:  Bella Vivat; Lucy Bemand-Qureshi; Jane Harrington; Sarah Davis; Patrick Stone
Journal:  Palliat Med       Date:  2019-02-12       Impact factor: 4.762

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.